Skip to main content
Clinical Trials/NCT06112548
NCT06112548
Recruiting
Not Applicable

The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral Total Knee Arthroplasty: a Randomized Controlled Trial

Damascus University1 site in 1 country80 target enrollmentMarch 1, 2024

Overview

Phase
Not Applicable
Intervention
Paracetamol
Conditions
Arthritis Knee
Sponsor
Damascus University
Enrollment
80
Locations
1
Primary Endpoint
perception of pain - first assessment
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This interventional study aims to compare the effectiveness of local multimodal drug periarticular injection in TKA patients with the standard pain control regime that includes opioids, NSAIDs, and other analgesics.

The main questions The investigators strive to answer are:

Is there a significant difference in the severity of pain and functional outcomes when applying periarticular injections? Are there any increased complications when applying the periarticular injections?

Detailed Description

The best pain control regime following TKA is controversial. While opioids have an excellent analgesic effect, they also have many side effects. The investigators are conducting a randomized controlled trial to compare the severity of pain following primary unilateral TKA when multimodal drug periarticular injunction is used with the standard pain control regime. The investigators will enroll patients undergoing primary unilateral TKA and randomly allocate them into one treatment group. The first will undergo the procedure with periarticular injection before the closure is composed of a mixture of 20ml of low body weight bupivacaine 5mg/ml plus 1ml of ketorolac 30mg/ml plus 0.5ml adrenaline 1mg/ml injected in medial and lateral retinaculum, medial and lateral collateral ligaments, quadriceps and patellar tendon, joint capsule, subcutaneous fat, and the second will go standard TKA with pain control using opioids, NSAIDS, and paracetamol. The severity of postoperative pain is the primary outcome studied, as well as preoperative complications and any drug side effects, the data will be collected by a fellow researcher who is blinded to the interventions, and the patients will be blinded too. Randomization will be done by a research fellow who is not involved in patient treatment or care.

Registry
clinicaltrials.gov
Start Date
March 1, 2024
End Date
November 30, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • all patients with end-stage arthritis of the knee going primary unilateral total knee arthroplasty.

Exclusion Criteria

  • inflammatory and secondary arthritis of the knee.
  • Patients who are allergic to one or more of the drugs used in the injections.
  • Patients who are already taking opioids for whatever reason or have a history of addiction.
  • BMI less than 20 and more than
  • patients with intra-operative complications that would affect the outcomes measurement.
  • Patients who are going through complex primary or revision TKA.
  • Pregnancy, renal or liver failure.
  • Patients who are classified as grade 3 or more according to ASA.

Arms & Interventions

TKA with pain management by IV/oral analgesics.

Patients going TKA and getting a standard pain control regime of IV opioids when needed, IV ketorolac, and IV/oral paracetamol.

Intervention: Paracetamol

TKA with pain management by multimodal periarticular injection.

Patients going TKA and getting an injection of a mixture of 20ml of low body weight bupivacaine 5mg/ml plus 1ml of ketorolac 30mg/ml plus 0.5ml adrenaline 1mg/ml injected in medial and lateral retinaculum, medial and lateral collateral ligaments, quadriceps and patellar tendon, joint capsule, subcutaneous fat before closure.

Intervention: primary unilateral TKA

TKA with pain management by multimodal periarticular injection.

Patients going TKA and getting an injection of a mixture of 20ml of low body weight bupivacaine 5mg/ml plus 1ml of ketorolac 30mg/ml plus 0.5ml adrenaline 1mg/ml injected in medial and lateral retinaculum, medial and lateral collateral ligaments, quadriceps and patellar tendon, joint capsule, subcutaneous fat before closure.

Intervention: Bupivacain

TKA with pain management by multimodal periarticular injection.

Patients going TKA and getting an injection of a mixture of 20ml of low body weight bupivacaine 5mg/ml plus 1ml of ketorolac 30mg/ml plus 0.5ml adrenaline 1mg/ml injected in medial and lateral retinaculum, medial and lateral collateral ligaments, quadriceps and patellar tendon, joint capsule, subcutaneous fat before closure.

Intervention: Ketorolac

TKA with pain management by multimodal periarticular injection.

Patients going TKA and getting an injection of a mixture of 20ml of low body weight bupivacaine 5mg/ml plus 1ml of ketorolac 30mg/ml plus 0.5ml adrenaline 1mg/ml injected in medial and lateral retinaculum, medial and lateral collateral ligaments, quadriceps and patellar tendon, joint capsule, subcutaneous fat before closure.

Intervention: epinephrine

TKA with pain management by multimodal periarticular injection.

Patients going TKA and getting an injection of a mixture of 20ml of low body weight bupivacaine 5mg/ml plus 1ml of ketorolac 30mg/ml plus 0.5ml adrenaline 1mg/ml injected in medial and lateral retinaculum, medial and lateral collateral ligaments, quadriceps and patellar tendon, joint capsule, subcutaneous fat before closure.

Intervention: Tramadol

TKA with pain management by IV/oral analgesics.

Patients going TKA and getting a standard pain control regime of IV opioids when needed, IV ketorolac, and IV/oral paracetamol.

Intervention: primary unilateral TKA

TKA with pain management by IV/oral analgesics.

Patients going TKA and getting a standard pain control regime of IV opioids when needed, IV ketorolac, and IV/oral paracetamol.

Intervention: Ketorolac

TKA with pain management by IV/oral analgesics.

Patients going TKA and getting a standard pain control regime of IV opioids when needed, IV ketorolac, and IV/oral paracetamol.

Intervention: Tramadol

Outcomes

Primary Outcomes

perception of pain - first assessment

Time Frame: measured 12 hours after surgery.

The severity of knee pain in the short postoperative period. As stated by the patient, on a scale of 0 to 10, 0 resents no pain at all, and 10 is the worst pain the participant can imagine.

perception of pain - second assessment

Time Frame: measured 24 hours after surgery.

The severity of knee pain in the short postoperative period. As stated by the patient, on a scale of 0 to 10, 0 resents no pain at all, and 10 is the worst pain the participant can imagine.

perception of pain - third assessment

Time Frame: measured 48 hours after surgery.

The severity of knee pain in the short postoperative period. As stated by the patient, on a scale of 0 to 10, 0 resents no pain at all, and 10 is the worst pain the participant can imagine.

functional status - first assessment

Time Frame: first measurement four weeks after surgery.

a "Knee Score" section (7 items) and a "Functional Score" section (3 items). Both sections are scored from 0 to 100 with lower scores being indicative of worse knee conditions and higher scores being indicative of better knee conditions. here, the investigator assesses the function section.

magnitude of disabling pain according to KSS - first assessment

Time Frame: first measurement four weeks after surgery.

a "Knee Score" section (7 items) and a "Functional Score" section (3 items). Both sections are scored from 0 to 100, with lower scores being indicative of worse knee conditions and higher scores being indicative of better knee conditions. Here the investigator assesses the pain section.

magnitude of disabling pain according to KSS - second assessment

Time Frame: first measurement six months after surgery.

a "Knee Score" section (7 items) and a "Functional Score" section (3 items). Both sections are scored from 0 to 100, with lower scores being indicative of worse knee conditions and higher scores being indicative of better knee conditions. Here the investigator assesses the pain section.

estimated total blood loss

Time Frame: measured once 48 hours after surgery.

the total amount of lost blood in the perioperative period and will be calculated using the Gross formula which is estimated by hitting the patients' blood volume by the difference between pre and post-operative hematocrit value divided by the initial hematocrit value

functional status - second assessment

Time Frame: second measurement six months after surgery.

a "Knee Score" section (7 items) and a "Functional Score" section (3 items). Both sections are scored from 0 to 100 with lower scores being indicative of worse knee conditions and higher scores being indicative of better knee conditions. here, the investigator assesses the function section.

Secondary Outcomes

  • perioperative complications(if happened within 6 months of surgery)
  • opioids consumption - frequency(measured once 48 hours after surgery.)
  • opioids consumption - dose(measured once 48 hours after surgery.)

Study Sites (1)

Loading locations...

Similar Trials